Arbutus Biopharma Corporation (ABUS)

[aries4747]

Interesting paragraph from 2020 Q4 transcript

From ABUS 2020 Q4 transcript: Dave Hastings, CFO

:And therefore, we believe our cash runway now extends through the third quarter of 2022. Finally, as a reminder, Arbutus owns approximately 16% of the common equity of Genevant Sciences, a company Arbutus launched with Roivant Sciences and to which Arbutus licensed exclusive rights to its LNP delivery technologies for RNA-based applications outside of HBV. We are entitled to receive tiered, low single-digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sublicenses the intellectual property, licensed by us to Genevant, we are entitled to receive upon the commercialization of a product developed by such sublicensee the lesser of 20% of the revenue received by Genevant for sublicensing and tiered, low single-digit royalties on product sales by the sublicensee.